This is a repost of a popular MAP, Market Access Podcast, from 1st of January 2023. 

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/ 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology